 The purpose of this study is to evaluate whether trough serum infliximab concentrations at the time of loss of clinical response will identify pediatric participants with inflammatory bowel disease IBD who would benefit regain clinical response from dose escalation above the currently approved dose 5 milligram mgkilogram kg every 8 weeks q8wk. 